CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-06-16 | Rivera Jose E EVP, General Counsel | Option exercise · Stock Option (right to buy) | −10,000 | 155,117 | ||
| 2020-06-03 | LEONARD JOHN M. President and CEO | Option exercise | +5,000 | $6.83 | $34K | 472,352 |
| 2020-06-03 | LEONARD JOHN M. President and CEO | Sale | −5,000 | $21.83 | $109K | 467,352 |
| 2020-06-03 | LEONARD JOHN M. President and CEO | Option exercise · Stock Option (right to buy) | −5,000 | 345,234 | ||
| 2020-05-26 | Rivera Jose E EVP, General Counsel | Option exercise | +10,000 | $6.83 | $68K | 285,722 |
| 2020-05-26 | Rivera Jose E EVP, General Counsel | Sale | −5,615 | $21.21 | $119K | 280,107 |
| 2020-05-26 | Rivera Jose E EVP, General Counsel | Option exercise · Stock Option (right to buy) | −10,000 | 165,117 | ||
| 2020-05-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2020-03-02 | LEONARD JOHN M. President and CEO | Grant or award · Stock Option (Right to Buy) | +340,000 | 340,000 | ||
| 2020-03-02 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2020-03-02 | Rivera Jose E EVP, General Counsel | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2020-03-02 | Goddard Glenn EVP, Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2020-03-02 | SCHIERMEIER ANDREW EVP, Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2020-01-03 | SCHIERMEIER ANDREW EVP, Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2019-08-01 | SCHIERMEIER ANDREW EVP, Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 | ||
| 2019-06-03 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2019-05-21 | Verwiel Frank Director | Grant or award · Stock Option (right to buy) | +19,000 | 19,000 | ||
| 2019-05-21 | KARSEN PERRY A Director | Grant or award · Stock Option (right to buy) | +19,000 | 19,000 | ||
| 2019-05-21 | GOODMAN JESSE Director | Grant or award · Stock option (right to buy) | +19,000 | 19,000 | ||
| 2019-05-21 | FORMELA JEAN FRANCOIS Director | Grant or award · Stock Option (right to buy) | +19,000 | 19,000 |
Page 33 of 40 · 783 trades